Charles River Associates (NASDAQ: CRAI), a worldwide leader in providing economic, financial, and management consulting services, today announced that Kenneth J. Beers has joined CRA as a Vice President in the Company’s Life Sciences Practice.

Mr. Beers supports biopharmaceutical clients across a range of topics involving development and commercialization of novel therapies, portfolio management, and business unit strategy. His 15 years of industry experience spans therapeutic areas and modalities on early-stage, pre-commercialization, and in-line therapies, as well as the integration of technologies such as diagnostics, software-as-a-medical-device, and bioinformatics.

“We’re excited to welcome Ken Beers to CRA,” said CRA’s President and Chief Executive Officer Paul Maleh. “Ken will join a diverse team of recognized life sciences experts who assist clients with commercialization and branding strategies, policy issues, pricing and market access, litigation, and more.”

“We look forward to working with Ken to address our clients’ most complex challenges,” said CRA’s Life Sciences Practice Leader and Vice President, Gregory K. Bell. “Ken brings an impressive set of skills to the team; in addition to supporting asset, portfolio, and business unit strategies for biopharmaceutical clients, we look forward to the focus he will bring to our continuing development of advanced analytics and strategic insights.”

Prior to joining CRA, Mr. Beers was a partner in an analytics company specializing in biopharma, medtech, and healthcare. He was previously the CEO of INTUS, a drug development platform that leverages proprietary biological network models to accelerate drug discovery.

Before starting his consulting career, Mr. Beers was an assistant professor of chemical engineering at the Massachusetts Institute of Technology. Mr. Beers holds a Bachelor of Chemical Engineering from Purdue University and a Ph.D. in Chemical Engineering from the University of Wisconsin-Madison.

About CRA’s Life Sciences Practice

The CRA Life Sciences Practice works with leading biotech, medical device, and pharmaceutical companies; law firms; regulatory agencies; and national and international industry associations. We provide the analytical expertise and industry experience needed to address our clients’ toughest issues. We have a reputation for rigorous and innovative analysis, careful attention to detail, and the ability to work effectively as part of a wider team of advisers.

About Charles River Associates (CRA)

Charles River Associates® is a leading global consulting firm specializing in economic, financial, and management consulting services. CRA advises clients on economic and financial matters pertaining to litigation and regulatory proceedings, and guides corporations through critical business strategy and performance-related issues. Since 1965, clients have engaged CRA for its unique combination of functional expertise and industry knowledge, and for its objective solutions to complex problems. Headquartered in Boston, CRA has offices throughout the world. Detailed information about Charles River Associates, a registered trade name of CRA International, Inc., is available at www.crai.com. Follow us on LinkedIn, Twitter, and Facebook.

SAFE HARBOR STATEMENT

Statements in this press release concerning the addition of Kenneth Beers, the Life Sciences Practice, future business Kenneth Beers may generate for CRA, and statements using the terms “expands,” “development” or similar expressions are “forward-looking” statements as defined in Section 21E of the Securities Exchange Act of 1934, as amended (the “Exchange Act”). These statements are based upon management’s current expectations and are subject to a number of factors and uncertainties. Although we believe there is a reasonable basis for these statements and assumptions, and these statements are expressed in good faith, these statements are subject to a number of additional factors and uncertainties, and actual performance and results may differ materially due to many important factors. Such factors that could cause actual performance or results to differ materially from any forward-looking statements made by CRA include, among others, the possibility that the demand for our services may decline as a result of changes in general and industry specific economic conditions; the timing of engagements for our services; the effects of competitive services and pricing; our ability to attract and retain key employee or non-employee experts; the inability to integrate and utilize existing consultants and personnel; the decline or reduction in project work or activity; global economic conditions including less stable political and economic environments; the potential impact of the COVID-19 pandemic on our operations and results; foreign currency exchange rate fluctuations; unanticipated expenses and liabilities; risks inherent in international operations; changes in tax law or accounting standards, rules, and regulations; our ability to collect on forgivable loans should any become due; and professional and other legal liability or settlements. Additional risks and uncertainties are discussed in our periodic filings with the Securities and Exchange Commission under the heading “Risk Factors.” The inclusion of such forward-looking information should not be regarded as our representation that the future events, plans, or expectations contemplated will be achieved. Except as may be required by law, we undertake no obligation to update any forward-looking statements after the date of this press release, and we do not intend to do so.

View source version on businesswire.com: https://www.businesswire.com/news/home/20220919005594/en/